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Abstract
Prion diseases, or transmissible spongiform
encephalopathies (TSEs), are a group of invariably fatal
neurodegenerative disorders.  Uniquely, they may present as
sporadic, inherited, or infectious forms, all of which involve
conversion of the normal cellular prion protein (PrPC) into a
pathogenic likeness of itself (PrPSc). Formation of neurotoxic
PrPSc and/or loss of the normal function of native PrPC result in
activation of cellular pathways ultimately leading to neuronal
death. Prion diseases can affect both humans and animals, with
scrapie of sheep, bovine spongiform encephalopathy (BSE), and
Creutzfeldt-Jakob disease being the most notable.  This review
is intended to provide an overview of the salient scientific
discoveries in prion research, mainly from a molecular
perspective.  Further, some of the major outstanding questions
in prion science are highlighted.  Prion research is having a
profound impact on modern medicine, and strategies for
prevention and treatment of these disorders may also find
application in the more common neurodegenerative diseases.
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Introduction
The idea of disease-causing protein particles was first put
forward in 1982 by Stanley B. Prusiner, the neurologist who
coined the term ‘prion’ (from proteinaceous infectious particle).
He was subsequently awarded the 1997 Nobel Prize in
Physiology and Medicine for this discovery, a discovery that
heralded the start of a new chapter in medical textbooks. Prion
diseases, or transmissible spongiform encephalopathies (TSEs),
are a group of fatal neurodegenerative disorders that affect both
humans and animals.1 Human prion diseases are unique in that
they can have a sporadic, inherited, or transmissible aetiology.2
The hallmark event in all TSEs appears to be the misfolding of
the normal cellular prion protein (PrPC), which is found
predominantly on the outer surface of neurons, into an insoluble
protease-resistant conformation (PrPSc).  The abnormal PrPSc
isomer is then believed to catalyse the conversion of normal
PrPC into a likeness of itself.  In sporadic prion disease, this
change in protein structure occurs spontaneously, as a chance
event, or possibly because of a somatic mutation in the prion
gene which destabilises PrPC  and increases the likelihood for
the conformational conversion to occur.  In the familial prion
diseases, it is the inherited genetic mutation that directly
predisposes to this conversion. In the transmissible scenario,
the interaction of host PrPC with exogenously introduced PrPSc
initiates the autocatalytic process.  In all three situations, the
end result is loss of function of the native PrPC coupled with a
toxic gain-of-function of aggregated PrPSc.  To date, various
experiments support the idea that the sole agent required for
transmission of prion disease is simply the abnormal prion
protein isoform.3 For instance, it has been found that familial
forms of human prion disease can be transmitted to laboratory
animals by inoculation.  Naturally, PrPSc requires endogenous
host PrPC to propagate: knock-out transgenic mice that lack
prion protein expression (Prnp0/0) are completely resistant to
PrPSc infection. 4 Indeed, this form of pathogenesis is unique
among human disease, and a revolutionary idea in clinical
medicine.
BSE and variant CJD
Most cases of human prion disease are sporadic; sporadic
Creutzfeldt-Jakob disease (CJD) occurs in a random distribution
all over the world and has an annual incidence of one per million.
The inherited group make up approximately 15% of human
prion disease, and all cases to date have been associated with
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coding mutations in the prion protein gene.  The use of genetic
diagnosis has in fact resulted in the inclusion of some atypical
dementias and fatal familial insomnia as part of the spectrum
of human prion disease.2 It is transmissible CJD which, however,
has attracted the lion’s share of public and media attention; the
first case of variant CJD (vCJD) was described in 1995 in the
UK, and since then speculation has been rife about a possible
epidemic.5 The story most likely began when the infectious agent
that causes scrapie in sheep crossed the species barrier to
bovines to cause bovine spongiform encephalopathy (BSE).  This
happened in the UK and not elsewhere because of the relatively
high incidence of scrapie in the UK, as well as the elimination
of a step in the processing of livestock carcasses that allowed
the infectious prion to survive.6 Then, once the species barrier
from sheep to cattle had been crossed, recycling of the bovine-
adapted scrapie amplified the infection and resulted in a BSE
epidemic.  That BSE originated from contaminated meat and
bone meal has been vindicated by the fact that the 1988 ban on
such products effectively halted the spread of BSE.7 Meanwhile,
however, the infectious prion agent had progressed further: it
had also managed to pass on from bovines to humans, giving
rise to vCJD (i.e. human-adapted BSE).  To date, over 130
victims have been claimed by vCJD, ascribed to consumption
of BSE-contaminated foodstuffs as the most likely explanation.
That BSE and vCJD are caused by the same prion strain is now
a well-confirmed scientific fact. 2 To start with, molecular strain
typing studies have shown that all cases of vCJD are associated
with the type of PrPSc  that is also observed in BSE, whilst
differing from the PrPSc types found in sporadic CJD.  Moreover,
it has been demonstrated that human vCJD prions precisely
duplicate the properties of native bovine BSE prions in their
behaviour on transmission to experimental mice. 8 This is a very
strong argument for an aetiological link between BSE and vCJD.
Finally, it must be mentioned that BSE-like prion strains have
been identified as the cause of novel spongiform
encephalopathies in various animal species, such as domestic
and captive wild cats (feline spongiform encephalopathy)
including cheetahs, pumas and tiger, and in exotic ungulates
such as the bison, Arabian oryx, and others.  This transmission
of BSE prion to other species constitutes an additional potential
risk to human health.
Prion transmission in variant CJD
Transmission of infectious prions does not occur by direct
contact, but via the peroral or parenteral routes.9 In an oral
uptake scenario, prions have to make their way from the
gastrointestinal tract to the central nervous system (CNS).
Interestingly, both intestinal epithelial cells and lymphoid cells
are known to express PrPC, thereby making ideal vehicles for
prion transmission.  It is thought that following oral uptake,
prions first gain entry into the intestinal mucosa, perhaps
through antigen-presenting M cells, and then proceed to reach
various gut-associated lymphoid tissue (GALT) components and
submucosal/myenteric enteric nervous system ganglia.
Thereafter, prion infection spreads from the gut to the brain
along the peripheral nervous system, either directly via the vagus
nerve, or via the spinal cord through the sympathetic nervous
system.10 Pathological PrP can be detected in tonsils, lymph
nodes, spleen, and appendix, even in the preclinical stages of
the disease.11 As regards the role of blood in transmission, suffice
it to say that using the macaque model it has been shown that
BSE can be transmitted from primate to primate in 25 months
by the intravenous administration of infected brain homogenate
solution. 12  Also, the BSE agent adapts to macaques in the same
way as it does to humans: examination of macaque brain
inoculated with vCJD (macaque vCJD) revealed a similar
pathology to that with second-passage BSE (macaque-adapted
BSE).12  Indeed, human-adapted BSE is more virulent for
humans than cattle BSE and is efficiently transmitted by the
peripheral route. 12 Clearly, therefore, the risk of iatrogenic
transmission of vCJD through surgical instruments, grafts, or
blood transfusion is real but at the same time difficult to assess.
In a recent study on the experimental transmission of surface-
bound infectious prions it was reported that five minutes of
contact with brains of scrapie-infected mice sufficed for a
stainless steel wire to acquire a maximum load of infectivity.9
Documented cases of iatrogenic CJD include those resulting
from transmission via neurosurgical instruments, human dura
mater grafts, corneal transplants, and treatment with human
pituitary hormones (growth hormone and gonadotrophin).13 All
these transmissions involved parenteral inoculation either by
surgical or by intramuscular injection. Mean incubation periods
varied from 1-2 years in neurosurgical transmission (in view of
direct cross-contamination with material in or adjacent to the
brain), to 10-15 years in human pituitary hormone treatment.
There is uncertainty as to the risk of transmission of CJD by
blood products, particularly since the presence of CJD infectivity
in human blood is still not clearly established. In contrast, blood
infectivity in rodent models of CJD has been well described and
is detected in the incubation period, well before onset of
neurological signs.  14 Quite recently, the national CJD
surveillance unit in the United Kingdom reported a case of vCJD
who had received a blood transfusion from a donor who later
died of vCJD15 ; moreover, a case of preclinical vCJD was also
identified in a patient who died from a non-neurological disorder
just 5 years after receiving blood transfusion from a donor who
later developed vCJD.16 These findings certainly raise the
likelihood of transmission of vCJD by blood transfusion.
Guidelines have been drawn up in some countries to
minimize the risk of iatrogenic transmission of CJD and modern
sterilization techniques, for example porous autoclaving at 134oC
for 18 minutes, have been demonstrated to significantly reduce
infectivity. Human growth hormone was withdrawn in many
countries in 1985 and has been replaced by recombinant
therapy. Dura mater grafts are no longer used in many countries.
In the UK, leuco-depletion of all blood donations has been
introduced, while individuals at greater risk of developing CJD
have been excluded as blood donors in many countries. These
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measures significantly reduce the possibility of iatrogenic
transmission of CJD, but do not exclude it.
The “species barrier”
The likelihood of transmission of prion disease from one
mammalian species to another is limited by the so-called
‘species-barrier’.  In other words, same-species transmission of
prions is typically highly efficient, whilst there is a relative lack
of susceptibility of one species to prions derived from another
species.  The biological consequence of a species barrier is thus
an increase in mean incubation time and a reduction in the
fraction of animals succumbing to disease.  The molecular basis
of the species barrier is believed to reside in differences between
the primary amino acid sequence of the host and inoculum prion
proteins.  To cite an example, transgenic mice expressing
hamster PrPC are much more susceptible than wild-type mice
to infection with hamster PrPSc.17 However, the ‘species
difference’ is not the only determinant.  For instance, classical
CJD prions and vCJD prions do not transmit equally to wild-
type mice, even though both prion strains have the identical
primary structure of human PrPC: in fact, vCJD prions transmit
much more readily than do CJD prions from sporadic disease.19
Evidently, factors like tertiary and quaternary protein structures
also influence prion propagation.  Overlap between a
thermodynamically favoured PrPSc conformation and that of the
host PrPC might therefore result in relatively easy transmission
between two species.  In this respect, BSE prions might
represent a particularly stable PrPSc conformation that is also
favoured by PrPC from a wide range of different species, thereby
accounting for the remarkable promiscuity of this strain in
mammals.  Regarding species barriers, recent data has emerged
that has proved quite unsettling.   In particular, conventional
mice were considered to have a high barrier to hamster PrPSc
inoculation since no clinical signs of scrapie develop in such
mice within their normal lifespan.  Nevertheless, careful study
revealed the presence of high PrPSc titers in their brains.
Moreover, infectivity was successfully passaged from the
scrapie-inoculated asymptomatic wild-type mice to both other
mice and hamsters.  In effect, this was a demonstration of
subclinical prion infection, where animals can harbour high
levels of infectivity without developing clinical signs of prion
disease.20 Such results seriously put to question our current
definition of the species barriers, which has classically been
based on clinical end-points.
Clinical features and diagnosis
of classical and variant CJD
Sporadic CJD usually affects individuals between the ages
of 45 and 75 years, and presents as a rapidly progressive
dementia.  Typically, onset is subtle and followed by a very rapid
deterioration, with a total duration of less than 6 months.
Prodromal complaints include relatively non-specific symptoms
like fatigue, malaise, insomnia, dizziness, and memory
difficulties.  Later, neurological symptoms and signs develop
rapidly: difficulty with gross and fine motor movements,
myoclonus, cerebellar ataxia, aphasia, eating and/or swallowing
difficulties.  In variant CJD, the person affected is typically under
50 years of age, often under 30, and initially psychiatric
symptoms predominate, together with non-specific fatigue and
sleep disturbance.  The most prominent psychiatric
manifestation is depression; however, apathy, withdrawal,
anxiety, aggression, delusions, and auditory and visual
hallucinations are also encountered.  With disease progression,
neurological problems arise: painful sensory symptoms, ataxia,
chorea, rigidity, aphasia, blurred vision and diplopia.  In contrast
to sporadic CJD, dementia usually develops later in the clinical
course of vCJD.
Until recently, the clinical diagnosis of CJD relied mainly
on a detailed case history and typical EEG findings.21 The latter
consist of characteristic periodic and pseudoperiodic sharp or
triphasic wave complexes of 0.5 to 2.0 Hz against a slow
background.  A negative EEG does not exclude the diagnosis of
CJD, particularly in the variant form.  Criteria have been
extended to include CSF analysis (e.g. 14-3-3 protein) for
sporadic CJD and MRI scans in vCJD.22 The level of 14-3-3
protein increases in neuronal death, and is therefore not specific
for CJD. However, levels of the gamma-isoform of 14-3-3 in
CSF samples from CJD patients were found to be significantly
higher than those observed in patients with non-CJD demetias.18
Typical MRI changes include increased signal in the basal
ganglia in sporadic CJD, contrasting with a posterior thalamic
high signal in vCJD.23 Additionally, vCJD can be diagnosed by
detection of vCJD-specific PrPSc on Western blot of a tonsil
biopsy; there is no comparable involvement of tonsil and other
lymphoreticular tissues in classical CJD.24 Brain biopsy has also
been used to diagnose CJD in life and may have a high diagnostic
accuracy. However, a negative biopsy result does not exclude
the diagnosis of CJD because of the possibility of sampling error,
and the procedure does have risks to the patient. A firm
diagnosis of CJD, therefore, often depends on neuropathological
examination post-mortem. In common with other TSEs,
neuropathological characteristics include neuronal cell loss,
spongiform degeneration, and gliosis with hyperastrocytosis;
the neuropathological hallmark of vCJD is the presence of
numerous florid amyloid plaques throughout the cerebral and
cerebellar cortices.25 There is hence an urgent need for the
development of sensitive assays based on blood or urine for ante
mortem diagnosis of BSE/vCJD.  A problem here is that the
concentration of PrPSc in the blood is much lower than in the
CNS; in particular, in human prion disease PrPSc has not been
demonstrated in the blood.  Thus, novel immunoassays and
immunoquantitative PCR assays are being developed for
ultrasensitive detection of the TSE agent.  Also, an antibody has
been generated which specifically recognizes PrPSc and can
discriminate between the different PrPSc  conformers from
sporadic and vCJD.  Preliminary data suggests that a reduced
expression of prion protein in the whole blood of patients with
vCJD may be useful as a surrogate marker for vCJD.
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Regarding host susceptibility to the development of CJD,
the role of the polymorphism in the prion protein gene at codon
129 should be mentioned. At PrP codon 129, an amino acid
polymorphism for methionine valine has been identified. In the
general Caucasian population, the frequencies for the codon-
129 polymorphism are 12% Val/Val, 37% Met/Met, and 51%
Met/Val.2 This contrasts with sporadic CJD patients, most of
whom are homozygous for methionine or valine, or variant CJD
cases all of whom to date have had a methionine homozygosity.2
Very recently, however, preclinical CJD was found in a PrP
codon 129 heterozygous individual, suggesting that
susceptibility to vCJD infection may not be confined to the
methionine homozygous genotype.16
Mechanisms of spongiform
neurodegeneration
Another unanswered question in prion science pertains to
the pathogenic cascades that result in neuronal loss.3,26 PrP
conversion might promote disease either by loss of function of
the natively folded PrPC or by gain of toxic activity of PrPSc.
Concerning the latter, neurografting experiments have revealed
that despite formation of substantial amounts of PrPSc in the
brain, Prnp0/0 neurons remain unaffected.27 A possible
explanation of these results is that PrPSc deposited extracellularly
is not, in itself, damaging to neurons and that prion-induced
neurodegeneration is instead the consequence of de novo PrPSc
formation at the cell surface or within cells.  The question of
whether loss of function of PrPC contributes to pathogenesis
cannot be ascertained until the normal physiology of PrPC in
the brain is unravelled.28 The prion protein is highly conserved
in mammalian species39 and although expressed most
abundantly in the brain, it has also been detected in other non-
neuronal tissues as diverse as lymphoid cells, lung, heart, kidney,
gastrointestinal tract, muscle and mammary glands.29 Such
properties point to a basic biological role of the molecule.  The
most salient observations of prion physiology can be
summarized as: (i) a role in copper homeostasis, particularly at
the pre-synaptic membrane; 30,31  (ii) involvement in signal
transduction cascades and calcium homeostasis; 31-36 and (iii)
involvement in cellular survival against copper and oxidative
stress. 37-38 Over the past years, evidence has been accumulating
that oxidative stress plays a central role in pathogenesis of
TSEs.40 To start with, lack of PrPC results in neuronal phenotypes
sensitive to oxidative stress.  Secondly, there is abundant
evidence of oxidative stress in cellular and animal models of
prion disease.  Thirdly, markedly increased levels of lipid and
protein oxidation were found in brain lysates from sporadic CJD
subjects.  In view of the above, anti-oxidant therapeutic
strategies are believed to have real potential in the treatment of
TSEs.
Conclusion
The future of prion research promises to be very challenging
and exciting.  Twenty or more human diseases are associated
with the deposition of ß-sheet-rich protein aggregates, or
amyloid.41 These include some neurodegenerative diseases, such
as Alzheimer’s, Parkinson’s, polyglutamine expansion,
amyotrophic lateral sclerosis, and prion diseases. Hence, prion
research is also contributing to our knowledge of how pathogenic
aggregation-prone proteins compromise neuronal plasticity and
survival.42 Research at a more fundamental level could identify
a prominent role for prion-like mechanisms, in which a protein
achieves a self-perpetuating state, in several different biological
contexts.  This novel concept in biology has already been found
to operate in long-term memory storage.43 Last, but not least, it
is necessary to sustain worldwide CJD surveillance regardless
of national BSE incidence and to take all precautionary measures
to avoid iatrogenic transmissions of vCJD.
References
1. Prusiner SB. Prions. Proc Natl Acad Sci USA 1998; 95:13363-83.
2. Collinge J. Prion diseases of humans and animals: their causes
and molecular basis. Annu Rev Neurosci 2001; 519-50.
3. Kretzschmar HA. Molecular pathogenesis of prion diseases. Eur
Arch Psychiatry Clin Neurosci 1999; 249:56-63.
4. Bueler H, Aguzzi A, Sailer A, et al. Mice devoid of PrP are
resistant to scrapie. Cell 1993; 73:1339-47.
5. Collinge J. Variant Creutzfeldt-Jakob disease. Lancet 1999;
354:317-23.
6. Brown P. Bovine spongiform encephalopathy and variant
Creutzfeldt-Jakob disease. BMJ 2001; 322:841-44.
7. Wilesmith JW, Ryan JB, Stevenson MA, et al. Temporal aspects
of the epidemic of bovine spongiform encephalopathy in Great
Britain: holding-associated risk factors for the disease. Vet Rec
2000; 147:319-25.
8. Scott MR, Will R, Ironside J, et al. Compelling transgenetic
evidence for transmission of bovine spongiform encephalopathy
prions to humans. Proc Natl Acad Sci USA 1999; 96:15137-42.
9. Weissmann C, Enari M, Klˆn OC, et al. Transmission of prions.
Proc Natl Acad Sci USA 2002; 99:16378-83.
10. Glatzel M, Aguzzi A. PrP(C) expression in the peripheral nervous
system is a determinant of prion neuroinvasion. J Gen Virol
2000; 81:2813-21.
11. Ramasamy I, Law M, Collins S, et al. Organ distribution of prion
proteins in variant Creutzfeldt-Jakob disease. Lancet Infect Dis
2003; 3:214-22.
12. Lasmezas CI, Fournier JG, Nouvel V, et al. Adaptation of the
bovine spongiform encephalopathy agent to primates and
comparison with Creutzfeldt-Jakob disease: implications for
human health. Proc Natl Acad Sci USA 2001; 98:4142-7.
13. Will RG. Acquired prion disease: iatrogenic CJD, variant CJD,
kuru. Br Med Bull 2003; 66:255-65.
14. Casaccia P, Ladogano L., Xi YG, et al. Levels of infectivity in the
blood throughout the incubation period of hamsters peripherally
injected with scrapie. Arch Virol 1989; 108:145-9.
15. Llewlyn CA, Hewitt PE, Knight RS, et al. Possible transmission of
variant Creutzfeldt-Jakob disease by blood transfusion. Lancet
2004; 363:417-21.
16. Peden AH, Head MW, Ritchie DL, et al. Preclinical vCJD after
blood transfusion in a PRNP codon 129 heterozygous patient.
Lancet 2004; 364:477-9.
17. Prusiner SB, Scott M, Foster D, et al. Transgenetic studies
implicate interactions between homologous PrP isoforms in
scrapie prion replication. Cell 1990; 63:673-86.
Malta Medical Journal     Volume 16   Issue 04   November 2004 19
18. Peoch K, Schroder HC, Laplanche J, et al. Determination of 14-3-
3 protein levels in CSF from Creutzfeldt-Jakob disease patients
by a highly sensitive capture assay. Neurosci Lett 2001;
301:167-70.
19. Hill AF, Desbruslais M, Joiner S, et al. The same prion strain
causes vCJD and BSE. Nature 1997; 389:448-50.
20. Hill AF, Joiner S, Linehan J, et al. Species-barrier-independent
prion replication in apparently resistant species. Proc Natl Acad
Sci USA 2000; 97:10248-53.
21. Poser S, Zerr I, Schroeter A, et al. Clinical and differential
diagnosis of Creutzfeldt-Jakob disease. In: Prion diseases –
diagnosis and pathogenesis (Groschup MH and Kretzschmar HA,
eds), Springer-Verlag, 2000; 153-59.
22. Kretzschmar HA. Diagnosis of prion diseases. Clin Lab Med
2003; 23:109-28.
23. Pandya HG, Coley SC, Wilkinson ID, et al. Magnetic resonance
spectroscopic abnormalities in sporadic and variant Creutzfeldt-
Jakob disease. Clin Radiol 2003; 58:148-53.
24. Hill AF, Butterworth RJ, Joiner S, et al. Investigation of variant
Creutzfeldt-Jakob disease and other human prion diseases with
tonsil biopsy samples. Lancet 1999; 353:183-9.
25. Will RG, Ironside JW, Zeidler M, et al. A new variant of
Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347:921-25.
26. Giese A, Kretzschmar HA. Prion-induced neuronal damage-the
mechanisms of neuronal destruction in the subacute spongiform
encephalopathies. Curr Top Microbiol Immunol 2001;
253:203-17.
27. Brandner S, Raeber A, Sailer A, et al. Normal host prion protein
(PrPC) is required for scrapie spread within the central nervous
system. Proc Natl Acad Sci USA 1996; 93:13148-51.
28. Hetz C, Maundrell K, Soto C. Is loss of function of the prion
protein the cause of prion disorders? Trends Mol Med 2003;
9:237-43.
29. Harris DA, Lele P, Snider WD. Localization of the mRNA for a
chicken prion protein by in situ hybridization. Proc Natl Acad Sci
USA 1993; 90:4309-13.
30. Kretzschmar HA, Tings T, Madlung A, et al. Function of PrPC as a
copper-binding protein at the synapse. Arch Virol Suppl 2000;
16:239-49.
31. Vassallo N, Herms J. Cellular prion protein function in copper
homeostasis and redox signalling at the synapse. J Neurochem
2003; 86:538-44.
32. Korte S, Vassallo N, Kramer ML, et al. Modulation of L-type
voltage-gated calcium channels by recombinant prion protein. J
Neurochem 2003; 87:1037-42.
33. Herms JW, Korte S, Gall S, et al. Altered intracellular calcium
homeostasis in cerebellar granule cells of prion protein-deficient
mice. J Neurochem 2000; 75:1487-92.
34. Kourie JI. Mechanisms of prion-induced modifications in
membrane transport properties: implications for signal
transduction and neurotoxicity. Chem Biol Interact 2001;
138:1-26.
35. Mouillet-Richard S, Ermonval M, Chebassier C, et al. Signal
transduction through prion protein. Science 2000; 289:1925-8.
36. Schneider B, Mutel V, Pietri M, et al. NADPH oxidase and
extracellular regulated kinases 1/2 are targets of prion protein
signaling in neuronal and nonneuronal cells. Proc Natl Acad Sci
USA 2003; 100:13326-31.
37. Roucou X, Gains M, LeBlanc AC. Neuroprotective functions of
prion protein. J Neurosci Res 2004; 75:153-61.
38. Chen S, Mange A, Dong L, et al. Prion protein as trans-
interacting partner for neurons is involved in neurite outgrowth
and neuronal survival. Mol Cell Neurosci 2003; 22:227-33.
39. Kretzschmar HA, Stowring LE, Westaway D, et al. Molecular
cloning of a human prion protein cDNA. DNA 1986; 5:315-24.
40. Milhavet O, Lehmann S. Oxidative stress and the prion protein in
transmissible spongiform encephalopathies. Brain Res Brain Res
Rev 2002; 38:328-39.
41. Thompson AJ, Barrow CJ. Protein conformational misfolding
and amyloid formation: characteristics of a new class of disorders
that include Alzheimer’s and prion diseases. Curr Med Chem
2002; 9:1751-62.
42. Mattson MP, Sherman M. Perturbed signal transduction in
neurodegenerative disorders involving aberrant protein
aggregation. Neuromolecular Med 2003; 4:109-32.
43. Si K, Lindquist S, Kandel ER. A neuronal isoform of the aplysia
CPEB has prion-like properties. Cell 2003; 115:879-91
Corinthia Group Prize in Paediatrics, 2004
Dr Jacques Diacono was this year’s successful prize
winner in Paediatrics, having obtained the top aggregate
mark over the combined examinations in Paediatrics in
the fourth and final year of the undergraduate course.
Dr Diacono also placed first overall in Medicine in this
year’s final examination. Competition for the now well-
established Corinthia Group Prize in Paediatrics was as
stiff as ever, with several candidates vying for the
honour! Indeed, we would sincerely like to congratulate
all those undergraduates (now doctors) who performed
admirably during the undergraduate course in
Paediatrics. We would also like to offer our
congratulations to Dr Diacono, seen receiving a cheque
for Lm100 from Dr Simon Attard Montalto, Head
Department of Paediatrics. Finally, we are extremely
grateful to the Corinthia Group for their ongoing support
toward the Academic Department of Paediatrics.
